NasdaqGS:ALNYBiotechs
Is Alnylam Pharmaceuticals Fairly Priced After FDA Approval Drives 81.3% Rally in 2025?
Wondering if Alnylam Pharmaceuticals is actually good value right now? You are not alone, especially with all the hype and debate around biotech stocks lately.
The stock has leapt an impressive 81.3% year-to-date, despite dipping 11.0% in the last week and falling 7.2% over the past month. This demonstrates both breakout growth and some recent volatility.
Big moves like this have been driven by the company announcing FDA approvals for new RNAi therapies, as well as strategic partnerships...